MedElevator
Войти в исследования American heart journal plus : cardiology research and practice · 2026
Early efficacy of oral lipid lowering therapy in achieving LDL-C targets following acute coronary syndrome: A real-world observational study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gautam Ambresh Kumar, Prajapathi Sudesh, Singh Abhishek, Pradhan Akshyaya, Ali Wahid, Shukla Ayush, Bhandari Monika, Sharma Akhil, Vishwakarma Pravesh, Chaudhary Gaurav, Chandra Sharad, Sethi Rishi, Dwivedi Sudhanshu, Puri Raman
Аннотация
BACKGROUND: High-intensity statins are the cornerstone of post-ACS management. Real-world data frequently indicate suboptimal adherence and low attainment of guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets.
OBJECTIVE: This study aimed to evaluate the early efficacy of oral lipid-lowering therapy in achieving LDL-C targets following ACS in a recent cohort of Indian patients.
METHODS: This single-center prospective observational study enrolled 511 statin-naive ACS patients. High-intensity statin monotherapy (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) was initiated following diagnosis. Lipid profile, including total cholesterol, triglycerides, HDL-C, LDL-C, and VLDL-C, were assessed at baseline, Day 7, Day 14, and Day 28. Primary endpoints included the proportion of patients achieving LDL-C goals at Day 28.
RESULTS: 50.5% of patients achieved the 2019 ESC/EAS LDL-C target (<55 mg/dL) at day 28. Similarly, 68.9% achieved the 2018 ACC/AHA target (<70 mg/dL), and 44.6% achieved the 2020 Lipid Association of India (LAI) target (<50 mg/dL) at day 28. The mean LDL-C reduced from 73.43 ± 13.99 mg/dL at Day 0 to 61.26 ± 27.00 mg/dL at Day 28, corresponding to a 16.6% reduction from baseline. On multivariate analysis, baseline LDL-C, type 2 diabetes mellitus and multivessel coronary disease were found to be independent negative predictors for achieving LDL-C goal <50 mg/dL at day 28.
CONCLUSION: LDL-C target attainment following ACS remains suboptimal despite high-intensity statin therapy, highlighting the need for earlier and more intensive lipid-lowering strategies in high-risk Indian patients.
OBJECTIVE: This study aimed to evaluate the early efficacy of oral lipid-lowering therapy in achieving LDL-C targets following ACS in a recent cohort of Indian patients.
METHODS: This single-center prospective observational study enrolled 511 statin-naive ACS patients. High-intensity statin monotherapy (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) was initiated following diagnosis. Lipid profile, including total cholesterol, triglycerides, HDL-C, LDL-C, and VLDL-C, were assessed at baseline, Day 7, Day 14, and Day 28. Primary endpoints included the proportion of patients achieving LDL-C goals at Day 28.
RESULTS: 50.5% of patients achieved the 2019 ESC/EAS LDL-C target (<55 mg/dL) at day 28. Similarly, 68.9% achieved the 2018 ACC/AHA target (<70 mg/dL), and 44.6% achieved the 2020 Lipid Association of India (LAI) target (<50 mg/dL) at day 28. The mean LDL-C reduced from 73.43 ± 13.99 mg/dL at Day 0 to 61.26 ± 27.00 mg/dL at Day 28, corresponding to a 16.6% reduction from baseline. On multivariate analysis, baseline LDL-C, type 2 diabetes mellitus and multivessel coronary disease were found to be independent negative predictors for achieving LDL-C goal <50 mg/dL at day 28.
CONCLUSION: LDL-C target attainment following ACS remains suboptimal despite high-intensity statin therapy, highlighting the need for earlier and more intensive lipid-lowering strategies in high-risk Indian patients.